Drugs that systemically inhibit TNF-α, IL-17 and IL-23 cytokines such as infliximab, secukinumab, and ustekinumab have been proved to be effective and safe therapeutic agents for the treatment of psoriasis (Puig, 2017; Papp et al., 2021b). Here, IL17A is linked to psoriasis.